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No national benchmark figures exist for early mortality due to chemotherapy unlike for surgical interventions. Deaths within 30 days
of chemotherapy during a 6-month period were identified from the Royal Marsden Hospital electronic patient records. Treatment
intention – curative or palliative, cause of death and number of previous treatments – were documented. Between April 2005 and
September 2005, 1976 patients received chemotherapy with 161 deaths within 30 days of chemotherapy (8.1%). Of these, 124
deaths (77.0%) were due to disease progression. Of the other 37 deaths, 12 (7.5%) were related to chemotherapy, six each for solid
tumours and haematological malignancies, of which seven (4.3%) were due to neutropenic sepsis. For the remaining 25 deaths
(15.5%) there was insufficient information. There were more deaths after third and subsequent lines of therapy than with first and
secondlines of therapy. Only 12 of the 161 deaths occurred in patients who were receiving potentially curative chemotherapy to give
a mortality rate in breast and gastrointestinal malignancy of 0.5 and 1.5%, respectively. It is possible to audit mortality within 30 days of
chemotherapy and this should become a benchmark for standard practice nationally. Most deaths were due to disease progression in
the palliative setting. We practice this form of audit each quarter and feed back to the treating teams so that deaths are discussed and
practice monitored.
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Over the last three decades, there has been a large increase in both
the number of chemotherapy treatments available to cancer
patients and in their usage. There is clear evidence of the beneficial
effects of these treatments in terms of improving both survival and
cancer-related symptoms. There is also considerable experience in
the identification, grading and management of toxicities associated
with these treatments. Despite this, chemotherapy-related deaths
still occur and at the current time there is no formal monitoring of
the frequency of occurrence in the UK.
Clinical trials, in general, publish death rates related to
chemotherapy. However data outside the context of clinical trials
are more limited. Ohe et al (2001) provide one of the few
publications to deal specifically with treatment-related deaths
following chemotherapy in routine clinical practice. The outcome
of 926 patients diagnosed with lung cancer requiring chemo-
therapy with or without thoracic radiotherapy, at the National
Cancer Centre Hospital, East Japan, was audited retrospectively.
Fifty-two per cent of the patients had stage I–III lung cancer,
whereas the remaining 48% had stage IV disease. The authors
defined treatment-related deaths as all deaths within 4 weeks of
completing treatment without clear evidence of other causes. In
this series, 2.3% of patients died from chemotherapy-related
toxicity and 1.6% died from acute pneumonitis following thoracic
radiotherapy. Unsurprisingly, advanced clinical stage of cancer
and poor performance status correlated with an increased risk of a
chemotherapy-related death. Radford et al (1993) report a 5%
mortality rate owing to sepsis following routine chemotherapy for
small–cell lung cancer. Stephens et al (1994) found that 10% of
2196 patients with small-cell lung cancer entered into a series of six
randomised clinical trials conducted by the Medical Research
Council (MRC) Lung Cancer Working Party (LCWP) died within 3
weeks of the start of chemotherapy and that half of these deaths
may have been treatment-related.
A retrospective study of 267 patients, aged 60 years or over, with
intermediate or high-grade Non-Hodgkin’s lymphoma receiving
CHOP chemotherapy was conducted. This demonstrated a
chemotherapy-related death rate of 13%. Sixty-three per cent of
these deaths occurred after the first cycle of CHOP. Infection
accounted for 82% of these chemotherapy-related deaths. Again,
performance status was shown to be an independent prognostic
factor for treatment-related death (Gomez et al, 1998).
Auditing patient outcomes relating to a particular intervention
is not a new concept. In the early 1980s a confidential, anonymous
review of mortality associated with anaesthesia was set up in the
UK (Lunn and Mushin (1982)). The aim was to assess
perioperative information in the hope of improving the anaes-
thesia and hence patient outcomes. In 1982, this became a joint
surgical and anaesthetic venture named the Confidential Enquiry
into Perioperative Death (CEPOD). Owing to its success, by 1988
this had become the National Confidential Enquiry into Peri-
operative Deaths (NCEPOD) with the majority of funding provided
by the UK government. The first official report was published in
1990. NCEPOD was re-assessed in 2001 by the Grimley–Evans
review and it was recommended that its remit be extended to Revised 21 September 2006; accepted 29 October 2006
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sinclude medical as well as surgical deaths regardless of whether a
procedure had been performed. NCEPOD now encompasses
primary care deaths and ‘near misses’ in addition to hospital in-
patient events. As a result, the name was changed to National
Confidential Enquiry into Patient Outcome and Death (conveni-
ently still abbreviated to NCEPOD). Not surprisingly, this led to
the collection of a large volume of data. From 1 April 2004, routine
collection of deaths is no longer required, but rather specific
studies are focussed on certain procedures for example, the report
investigating in-patient deaths within 30 days of a therapeutic
endoscopic procedure. Since April 2005, NCEPOD now falls under
the auspices of the National Patient Safety Agency.
The increasing importance of clinical governance in relation to
all aspects of patient care and the expansion of the role of NCEPOD
led to the inception of this study. The aim was to monitor all
deaths within 30 days of chemotherapy at the Royal Marsden
Hospital and to identify whether deaths were treatment-related or
not. The period of 30 days conveniently fits with the most common
schedule for chemotherapy – a 21 or 28 day cycle, devised with the
intention that blood counts have returned to normal before further
treatment.
METHODS
The Royal Marsden Hospital is a large cancer centre in London,
UK. Patient records are stored electronically on the Electronic
Patient Record (EPR). In-patient deaths are automatically regis-
tered on the EPR. Patient deaths occurring outside the hospital are
added to the EPR as soon as the hospital team is notified.
Notification can be via the GP, family, local hospice or the cancer
registry. This audit was conceived in October 2003 followed by
development of the process and was approved by the Royal
Marsden Hospital Audit Liasion Group. The EPR database was
searched for all patients who had received one or more cycles of
chemotherapy between 1 April 2005 and 30 September 2005. The
EPR database was also used to identify patient case notes for all
patients who had died within 30 days of receiving a chemotherapy
treatment. These case notes were analysed by registrars/consultant
in medical oncology to identify the cause of death. When the cause
of death was not clearly apparent from the case notes, the GP or
hospice was contacted. Deaths were then categorised as being
treatment-related, non-treatment-related or inconclusive owing to
lack of information.
For the purposes of the study, the definition of chemotherapy
treatment included cytotoxic drugs and biological agents, such as
interferon and monoclonal antibody therapies. For those patients
identified to have died within 30 days of chemotherapy, additional
information was collected: specifically the patient’s age, gender,
primary cancer, the hospital unit providing treatment, the choice
of chemotherapy regimen, the number of lines of previous
chemotherapy treatment, the number of cycles of chemotherapy
of the current regimen received, median time to death following
chemotherapy and the place of death. Finally, for all identified
deaths it was determined whether the chemotherapy was given
with curative or palliative intent.
RESULTS
Between April 2005 and September 2005, 1976 patients received
chemotherapy treatment. During this 6-month period, 161 deaths
within 30 days of receiving chemotherapy treatment were
identified (8.1%). Table 1 demonstrates the demographic compo-
sition of the patients who died within this period of 30 days from
treatment. The median age of patients who died was 61 years
(range: 6–86 years). Fifty-three per cent of patients were female;
47% were male. The median time to death following treatment was
17 days (range 1–30 days). Eighty-one patients (50.3%) died while
an in-patient at the Royal Marsden, 43 patients (26.7%) died in a
hospice or another hospital, 23 (14.2%) at home and in 14 (8.6%)
of cases, the location of death was not recorded.
Of the 161 deaths within 30 days of receiving chemotherapy, 124
deaths (77%) were considered to be unrelated to chemotherapy
with the majority of deaths owing to progression of the underlying
malignancy (75.6%). Other less common causes of death were non-
neutropenic sepsis (16.2%), thrombo-embolism/cardiac arrest/
SVCO (8.9%) and bowel obstruction (2.4%). Twelve deaths
(7.5%) were considered related to chemotherapy: seven owing to
neutropenic sepsis (4.3%), four associated with multiorgan failure/
sepsis and one paediatric case attributed to chemotherapy toxicity
related to impaired renal function. Of the 12 deaths, six of these
patients were receiving treatment for a haemato-oncological
disorder (lymphoma, myeloma and leukaemia). On excluding
these haemato-oncology patients from the cohort, the total number
of chemotherapy-related deaths was six, therefore the rate of
deaths considered related to chemotherapy was 3.75% each for
solid tumours and haematological malignancies (Table 2). Analy-
sing each of the 12 chemotherapy-related deaths individually, seven
of these deaths (58.3%) occurred in patients receiving potentially
curative treatment, of which four patients were being treated for
haemato-oncological disease. For 25 deaths (15.5%) occurring
within 30 days of treatment, there was insufficient information to
establish whether death was treatment-related. In some of these
cases, treatment-related death cannot be ruled out.
Of the total 161 patient deaths within 30 days of receipt of
chemotherapy, 12 patients were receiving treatment with
potentially curative intent (i.e., neoadjuvant/adjuvant treatment)
(Table 2). Looking closer at treatment within the breast unit, a total
of 356 patients were treated with chemotherapy during this 6-
month period: 199 patients with neoadjuvant/adjuvant treatment
with curative intent and 167 patients with palliative intent. There
was one neoadjuvant treatment related event in this 6-month
period in the breast unit. This translates to a 0.5% mortality rate
following potentially curative breast cancer treatment. Within the
gastrointestinal (GI) unit, 349 patients were treated with che-
motherapy during this 6-month period – 133 patients with curative
intent, 216 patients with palliative intent. Two patient deaths
occurred within 30 days of treatment in the cohort of patients
receiving GI neoadjuvant/adjuvant treatment – a 1.5% treatment
related mortality rate (Table 3).
There were 44 patients (27%) who died while receiving their first
line of chemotherapy, 39 (24%) patients died after two lines of
chemotherapy treatment and 72 patients (45%) were on third line,
or subsequent lines of treatment (Table 4). In six cases (4%), the
line of therapy was not documented.
DISCUSSION
This audit describes results at the Royal Marsden for mortality
following chemotherapy treatment with curative and palliative
treatment, outside the context of a clinical trial. Like Ohe et al
Table 1 Demographics
Gender Male: 75 (47%) Female 86 (53%)
Age Median 61 years (range 6–86)
Time to death
following
chemotherapy
Median 17 days (range 1–30)
Place of death RMH 81 (50.3%)
Hospice/other hospital 43 (26.7%)
Home 23 (14.2%)
Not recorded 14 (8.6%)
RMH¼Royal Marsden Hospital.
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sTable 2 Cause of death
Division
Total number of
deaths identified
from HIS GI tract Urology Lung Breast Gynae
Clinical
pharmacology
Skin and
melonoma Sarcoma
Head
and neck Paediatrics Lymphoma Myeloma Leukaemia
Neuro-
Oncology Total
Likely cause of death
Progression of disease 12 2 13 16 6 2 5 10 4 2 4 4 10 3 93 (57%)
Liver failure 11
Thrombo-embolism/
cardiac arrest/SVCO
34 1 2 1 11
Bowel obstruction 1 2 3
Chemotherapy toxicity
related to impaired renal
function
11
Sepsis (non-
neutropenic)/multiorgan
failure/GVHD
41 3 3 1 2 1 1 4 20
Neutropaenic sepsis 0 0 1 2 (1) 1 0 0 0 1 1 7 (4%)
Summary of deaths
Unknown (Insufficient
Information)
1 2 3 9 6 0 3 1 0 0 0 0 0 0 25 (16%)
Total chemotherapy
unrelated deaths
19 3 19 21 10 2 5 12 6 3 5 5 10 3 124 (77%)
Total
chemotherapy
related deaths
0 0 2 2 (1) 0 0 1 0 1 0 1 5 0 12 (7%)
GI¼gastrointestinal; GvHD¼graft-versus-host disease; SVCO¼superior vena cava obstruction.
M
o
r
t
a
l
i
t
y
w
i
t
h
i
n
3
0
d
a
y
s
o
f
c
h
e
m
o
t
h
e
r
a
p
y
M
E
R
O
’
B
r
i
e
n
e
t
a
l
1
6
3
4
B
r
i
t
i
s
h
J
o
u
r
n
a
l
o
f
C
a
n
c
e
r
(
2
0
0
6
)
9
5
(
1
2
)
,
1
6
3
2
–
1
6
3
6
&
2
0
0
6
C
a
n
c
e
r
R
e
s
e
a
r
c
h
U
K
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s(2001) in Japan, this audit details low rates of treatment-related
death – occurring in 7.5% of patients receiving chemotherapy in
this particular 6-month time period (3.75% each for solid tumours
and haemato-oncological disease). For chemotherapy given with
curative intent, the mortality was 0.5 and 1.5% for the two
common tumour types where adjuvant chemotherapy is given
(breast and GI).
Following the collection of the quarterly data, deaths within this
time are reviewed on an individual basis by each treating team. For
example, the deaths within 30 days of chemotherapy within the
breast unit for this period were individually reviewed. Thirty-two
deaths occurred, 50% of these deaths attributed to progressive
disease. Both of the two treatment-related deaths were due to
neutropenic sepsis, one occurring in a patient receiving neo-
adjuvant treatment. Notably, of the 32 deaths, 21 patients (65.6%)
were receiving at least third-line treatment.
One of the weaknesses of this audit is the fact that 25 or 15.5% of
the deaths has insufficient information to ascribe them to
treatment or non-treatment related deaths. None of these patients
were receiving adjuvant chemotherapy or treatment in the curative
setting. Given that 77% of the deaths were due to progressive
disease, it is probable that around 19 of these 25 were also due to
progressive disease. If we ascribe the cause of death in the
remaining six patients as due to treatment, the overall death on
treatment rate could be 11.2%. Future audits need to focus on this
area to minimise the number of deaths from unknown causes.
Nevertheless, we feel this is an audit system that could be used
for oncology centres nationally.
Over 50% of those in the overall cohort were receiving second,
or later, lines of treatment. This was a population of highly treated
patients, with their associated morbidity. In this circumstance,
where the chances of response to multiple lines of treatment are
low, these benchmarking results will facilitate a more informed
discussion about the mortality rate following chemotherapy and
help patients to accurately weigh up the risks of treatment. A
recent audit at the Royal Marsden Hospital (RMH) by Kuciejewska
et al (2006) looked at the response rate to chemotherapy for
heavily pretreated breast cancer patients. For patients receiving
third-line chemotherapy for metastatic disease, who have achieved
at best stable disease in previous lines of metastatic treatment, the
response rate to this line of therapy is 20%, with a time to
progression of 3 months and a median survival of 6 months. The
results of this audit suggest that the rate of death within 30 days of
treatment in this group of third line chemotherapy treatment
patients is not insignificant at 12.6%. The potential fatal
complications of treatment must be balanced with the low chance
of benefit from treatment and require honest discussion with the
patient. Incorporating performance status to the data collection
may add extra weight to the decision-making process, with the
assumption that patients with a poor performance status at time of
chemotherapy have a greater mortality rate.
The study highlights the importance of accurate records and the
need for timely and accurate discharge summaries. The death
records depend on the involvement of the cancer registry and of
the family/hospice route of informing the hospital about patient
death. This has proved to be a useful exercise, which is in
Table 3 Curative treatment mortality rate – breast/GI
Treatment intent Breast unit GI unit
Neoadjuvant/adjuvant 199 (54%) 133 (38.1%)
Palliative 167 (46%) 216 (61.9%)
Total 366 349
Neo/adjuvant deaths 1 (0.5%) 2 (1.5%)
GI¼gastrointestinal.
T
a
b
l
e
4
L
i
n
e
s
o
f
t
r
e
a
t
m
e
n
t
D
i
v
i
s
i
o
n
T
o
t
a
l
n
u
m
b
e
r
o
f
d
e
a
t
h
s
i
d
e
n
t
i
f
i
e
d
f
r
o
m
H
I
S
G
I
t
r
a
c
t
U
r
o
l
o
g
y
L
u
n
g
B
r
e
a
s
t
G
y
n
a
e
C
l
i
n
i
c
a
l
p
h
a
r
m
a
c
o
l
o
g
y
S
k
i
n
a
n
d
m
e
l
o
n
o
m
a
S
a
r
c
o
m
a
H
e
a
d
a
n
d
n
e
c
k
P
a
e
d
i
a
t
r
i
c
s
L
y
m
p
h
o
m
a
M
y
e
l
o
m
a
L
e
u
k
a
e
m
i
a
N
e
u
r
o
-
O
n
c
o
l
o
g
y
T
o
t
a
l
T
o
t
a
l
n
o
.
o
f
d
e
a
t
h
s
2
0
5
2
4
3
2
1
7
2
8
1
4
6
4
5
6
1
5
3
1
6
1
P
a
t
i
e
n
t
s
o
n
1
s
t
l
i
n
e
t
h
e
r
a
p
y
1
1
2
1
1
3
3
0
4
4
0
2
0
1
2
1
4
4
(
2
7
%
)
P
a
t
i
e
n
t
o
n
2
n
d
l
i
n
e
t
h
e
r
a
p
y
1
0
6
7
3
0
3
8
6
1
1
0
2
1
3
9
(
2
4
%
)
P
a
t
i
e
n
t
s
o
n
3
r
d
l
i
n
e
o
r
s
u
b
s
e
q
u
e
n
t
t
h
e
r
a
p
y
7
3
6
2
1
1
0
2
0
2
0
1
4
5
1
0
1
7
2
(
4
5
%
)
L
i
n
e
o
f
t
h
e
r
a
p
y
n
o
t
k
n
o
w
n
/
n
o
t
a
p
p
l
i
c
a
b
l
e
1
0
1
1
1
0
1
0
0
0
0
0
1
0
6
(
4
%
)
T
o
t
a
l
n
o
.
o
f
d
e
a
t
h
s
r
e
l
a
t
e
d
t
o
n
e
o
-
a
d
j
u
v
a
n
t
/
a
d
j
u
v
a
n
t
t
r
e
a
t
m
e
n
t
s
2
0
0
1
0
0
0
0
1
1
(
1
)
0
2
4
0
1
2
Mortality within 30 days of chemotherapy
MER O’Brien et al
1635
British Journal of Cancer (2006) 95(12), 1632–1636 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
saccordance with the governance of NCEPOD. Just recently, there
has been a national movement to do a similar type of study with a
protocol ‘Systemic Anti-Cancer Therapies (SACT)’ going through
the NCEPOD steering group. Our data can contribute to creating a
benchmark upon which other yearly periods, and the data from
other hospitals, can be compared.
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